

---

## SeQuent Scientific to acquire the business of Arvee Synthesis

### Acquisition to provide impetus to Human API business

---

**Bangalore, May 22, 2014** SeQuent Scientific Limited today announced that it has entered into an definitive agreement to acquire the manufacturing assets and business of Arvee Synthesis Private Limited, Mysore ('Arvee'). Arvee would serve as a site for key intermediates for the Company's Human API business. The site has all necessary approvals and infrastructure with space for future expansion of SeQuent's rapidly expanding business.

In another development, Sequent also acquired a land admeasuring 14 acres 24 Guntas., adjacent to its existing FDA approved facility in Mangalore. The facility at Mysore and land at Mangalore would be used for meeting the growing demand of Sequent's key products in the USFDA and WHO regulated markets.

Speaking on the development, Manish Gupta, CEO of Sequent said : "Sequent's strategy of focusing on small, niche molecules is paying dividends. The human API business of Sequent is poised to grow at a CAGR of 50%+ in the medium term, on the back of regulatory approvals of its key products in the regulated markets".

#### **About Sequent Scientific Limited.**

SeQuent Scientific Limited, listed on the Bombay Stock Exchange Limited (stock code: 512529) is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. SeQuent is the world's largest producer of Anthelmintics.

Please visit [www.sequent.in](http://www.sequent.in) for additional information.

For additiona linformation, please contact

#### **SeQuent Scientific Limited**

Kannan P R, CFO  
Kannan.pr@sequent.in  
Tel: +91 80 67840327

Manish Gupta, CEO  
manish@sequent.in  
Tel: +91 22 41114714

Mr. Rohit Yagnik, Fortuna PR  
+91 98338 07272; [rohit@fortunapr.in](mailto:rohit@fortunapr.in)